QB3 Seminar: Martin Babler, CEO, Principia Biopharma
QB3 SEMINAR: MARTIN BABLER, FORMER CEO, PRINCIPIA BIOPHARMA. "BUILDING A BEST-IN-CLASS PLATFORM FOR IMMUNE-MEDIATED DISEASE" Sanofi recently acquired Principia Biopharma for $3.7 billion. Principia, founded in 2008, built a portfolio of drugs to treat immune-mediated conditions including multiple sclerosis, pemphigus and immune thrombocytopenia purpura, all currently in Phase 3 trials. The portfolio was developed using...